BRISTOL-MYERS SQUIBB CO (BRM.DE) Stock Fundamental Analysis
FRA:BRM • US1101221083
50.91 EUR
+0.53 (+1.05%)
Last: Feb 19, 2026, 05:17 PM
Taking everything into account, BRM scores 5 out of 10 in our fundamental rating. BRM was compared to 52 industry peers in the Pharmaceuticals industry. BRM has only an average score on both its financial health and profitability. BRM has a bad growth rate and is valued cheaply. BRM also has an excellent dividend rating. These ratings would make BRM suitable for value and dividend investing!
1. Profitability
1.1 Basic Checks
- In the past year BRM was profitable.
- In the past year BRM had a positive cash flow from operations.
- Of the past 5 years BRM 4 years were profitable.
- Of the past 5 years BRM 4 years had a positive operating cash flow.
1.2 Ratios
- BRM has a Return On Assets (6.23%) which is comparable to the rest of the industry.
- The Return On Equity of BRM (32.55%) is better than 80.77% of its industry peers.
- BRM's Return On Invested Capital of 17.64% is fine compared to the rest of the industry. BRM outperforms 73.08% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 6.23% | ||
| ROE | 32.55% | ||
| ROIC | 17.64% |
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
- BRM has a Profit Margin (12.57%) which is comparable to the rest of the industry.
- BRM's Profit Margin has improved in the last couple of years.
- With an excellent Operating Margin value of 33.51%, BRM belongs to the best of the industry, outperforming 82.69% of the companies in the same industry.
- In the last couple of years the Operating Margin of BRM has grown nicely.
- BRM has a Gross Margin of 73.15%. This is comparable to the rest of the industry: BRM outperforms 59.62% of its industry peers.
- BRM's Gross Margin has been stable in the last couple of years.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 33.51% | ||
| PM (TTM) | 12.57% | ||
| GM | 73.15% |
OM growth 3Y13.23%
OM growth 5Y20.59%
PM growth 3Y2.21%
PM growth 5YN/A
GM growth 3Y-2.43%
GM growth 5Y-0.33%
2. Health
2.1 Basic Checks
- The Return on Invested Capital (ROIC) is well above the Cost of Capital (WACC), so BRM is creating value.
- There is no outstanding debt for BRM. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
2.2 Solvency
- An Altman-Z score of 2.31 indicates that BRM is not a great score, but indicates only limited risk for bankruptcy at the moment.
- BRM has a Altman-Z score (2.31) which is comparable to the rest of the industry.
- The Debt to FCF ratio of BRM is 3.20, which is a good value as it means it would take BRM, 3.20 years of fcf income to pay off all of its debts.
- Looking at the Debt to FCF ratio, with a value of 3.20, BRM is in the better half of the industry, outperforming 67.31% of the companies in the same industry.
- BRM has a Debt/Equity ratio of 2.41. This is a high value indicating a heavy dependency on external financing.
- BRM has a worse Debt to Equity ratio (2.41) than 80.77% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 2.41 | ||
| Debt/FCF | 3.2 | ||
| Altman-Z | 2.31 |
ROIC/WACC2.06
WACC8.55%
2.3 Liquidity
- A Current Ratio of 1.27 indicates that BRM should not have too much problems paying its short term obligations.
- With a Current ratio value of 1.27, BRM perfoms like the industry average, outperforming 40.38% of the companies in the same industry.
- BRM has a Quick Ratio of 1.17. This is a normal value and indicates that BRM is financially healthy and should not expect problems in meeting its short term obligations.
- Looking at the Quick ratio, with a value of 1.17, BRM is in the better half of the industry, outperforming 69.23% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 1.27 | ||
| Quick Ratio | 1.17 |
3. Growth
3.1 Past
- BRM shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 439.47%, which is quite impressive.
- Measured over the past years, BRM shows a decrease in Earnings Per Share. The EPS has been decreasing by -0.92% on average per year.
- Looking at the last year, BRM shows a decrease in Revenue. The Revenue has decreased by -0.22% in the last year.
- BRM shows a small growth in Revenue. Measured over the last years, the Revenue has been growing by 2.54% yearly.
EPS 1Y (TTM)439.47%
EPS 3Y-7.62%
EPS 5Y-0.92%
EPS Q2Q%-24.55%
Revenue 1Y (TTM)-0.22%
Revenue growth 3Y1.45%
Revenue growth 5Y2.54%
Sales Q2Q%1.3%
3.2 Future
- Based on estimates for the next years, BRM will show a decrease in Earnings Per Share. The EPS will decrease by -4.54% on average per year.
- Based on estimates for the next years, BRM will show a decrease in Revenue. The Revenue will decrease by -5.61% on average per year.
EPS Next Y-1.05%
EPS Next 2Y-1.88%
EPS Next 3Y-3.16%
EPS Next 5Y-4.54%
Revenue Next Year-7.97%
Revenue Next 2Y-5.07%
Revenue Next 3Y-5.93%
Revenue Next 5Y-5.61%
3.3 Evolution
- The EPS growth rate is decreasing: in the next years the growth will be less than in the last years.
- The Revenue growth rate is decreasing: in the next years the growth will be less than in the last years.
4. Valuation
4.1 Price/Earnings Ratio
- BRM is valuated reasonably with a Price/Earnings ratio of 9.81.
- 90.38% of the companies in the same industry are more expensive than BRM, based on the Price/Earnings ratio.
- BRM is valuated cheaply when we compare the Price/Earnings ratio to 27.27, which is the current average of the S&P500 Index.
- Based on the Price/Forward Earnings ratio of 9.91, the valuation of BRM can be described as reasonable.
- BRM's Price/Forward Earnings ratio is rather cheap when compared to the industry. BRM is cheaper than 84.62% of the companies in the same industry.
- BRM's Price/Forward Earnings ratio indicates a rather cheap valuation when compared to the S&P500 average which is at 28.16.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 9.81 | ||
| Fwd PE | 9.91 |
4.2 Price Multiples
- BRM's Enterprise Value to EBITDA ratio is rather cheap when compared to the industry. BRM is cheaper than 92.31% of the companies in the same industry.
- Based on the Price/Free Cash Flow ratio, BRM is valued cheaply inside the industry as 100.00% of the companies are valued more expensively.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 8.02 | ||
| EV/EBITDA | 7.28 |
4.3 Compensation for Growth
- BRM has a very decent profitability rating, which may justify a higher PE ratio.
- A cheap valuation may be justified as BRM's earnings are expected to decrease with -3.16% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-1.88%
EPS Next 3Y-3.16%
5. Dividend
5.1 Amount
- BRM has a Yearly Dividend Yield of 4.21%, which is a nice return.
- BRM's Dividend Yield is rather good when compared to the industry average which is at 1.91. BRM pays more dividend than 84.62% of the companies in the same industry.
- BRM's Dividend Yield is rather good when compared to the S&P500 average which is at 1.85.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 4.21% |
5.2 History
- The dividend of BRM is nicely growing with an annual growth rate of 11.67%!
Dividend Growth(5Y)11.67%
Div Incr Years3
Div Non Decr Years3
5.3 Sustainability
- BRM pays out 82.81% of its income as dividend. This is not a sustainable payout ratio.
- The Dividend Rate of BRM has been growing, while earnings will be declining. This means the dividend growth is most likely not sustainable.
DP82.81%
EPS Next 2Y-1.88%
EPS Next 3Y-3.16%
FRA:BRM (2/19/2026, 5:17:09 PM)
50.91
+0.53 (+1.05%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)02-05 2026-02-05/bmo
Earnings (Next)04-30 2026-04-30
Inst Owners81.87%
Inst Owner ChangeN/A
Ins Owners0.02%
Ins Owner ChangeN/A
Market Cap103.64B
Revenue(TTM)48.19B
Net Income(TTM)6.04B
Analysts70.59
Price Target48.84 (-4.07%)
Short Float %N/A
Short RatioN/A
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 4.21% |
Yearly Dividend2.04
Dividend Growth(5Y)11.67%
DP82.81%
Div Incr Years3
Div Non Decr Years3
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)20.98%
Min EPS beat(2)6.92%
Max EPS beat(2)35.04%
EPS beat(4)4
Avg EPS beat(4)18.72%
Min EPS beat(4)6.92%
Max EPS beat(4)35.04%
EPS beat(8)8
Avg EPS beat(8)16.52%
EPS beat(12)11
Avg EPS beat(12)11.66%
EPS beat(16)15
Avg EPS beat(16)10.13%
Revenue beat(2)2
Avg Revenue beat(2)4.61%
Min Revenue beat(2)2.43%
Max Revenue beat(2)6.79%
Revenue beat(4)4
Avg Revenue beat(4)4.63%
Min Revenue beat(4)2.43%
Max Revenue beat(4)6.79%
Revenue beat(8)8
Avg Revenue beat(8)3.95%
Revenue beat(12)9
Avg Revenue beat(12)1.94%
Revenue beat(16)11
Avg Revenue beat(16)1.64%
PT rev (1m)3.55%
PT rev (3m)7.06%
EPS NQ rev (1m)-29.59%
EPS NQ rev (3m)-32.32%
EPS NY rev (1m)0.39%
EPS NY rev (3m)-0.06%
Revenue NQ rev (1m)0.44%
Revenue NQ rev (3m)0.02%
Revenue NY rev (1m)0.04%
Revenue NY rev (3m)0.77%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 9.81 | ||
| Fwd PE | 9.91 | ||
| P/S | 2.56 | ||
| P/FCF | 8.02 | ||
| P/OCF | 7.39 | ||
| P/B | 6.62 | ||
| P/tB | N/A | ||
| EV/EBITDA | 7.28 |
EPS(TTM)5.19
EY10.19%
EPS(NY)5.14
Fwd EY10.09%
FCF(TTM)6.35
FCFY12.46%
OCF(TTM)6.89
OCFY13.54%
SpS19.92
BVpS7.69
TBVpS-9.81
PEG (NY)N/A
PEG (5Y)N/A
Graham Number29.97
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 6.23% | ||
| ROE | 32.55% | ||
| ROCE | 23.41% | ||
| ROIC | 17.64% | ||
| ROICexc | 23.19% | ||
| ROICexgc | 118.19% | ||
| OM | 33.51% | ||
| PM (TTM) | 12.57% | ||
| GM | 73.15% | ||
| FCFM | 31.86% |
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3Y13.23%
OM growth 5Y20.59%
PM growth 3Y2.21%
PM growth 5YN/A
GM growth 3Y-2.43%
GM growth 5Y-0.33%
F-Score6
Asset Turnover0.5
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 2.41 | ||
| Debt/FCF | 3.2 | ||
| Debt/EBITDA | 2.13 | ||
| Cap/Depr | 26.84% | ||
| Cap/Sales | 2.75% | ||
| Interest Coverage | 7.66 | ||
| Cash Conversion | 79.11% | ||
| Profit Quality | 253.39% | ||
| Current Ratio | 1.27 | ||
| Quick Ratio | 1.17 | ||
| Altman-Z | 2.31 |
F-Score6
WACC8.55%
ROIC/WACC2.06
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)439.47%
EPS 3Y-7.62%
EPS 5Y-0.92%
EPS Q2Q%-24.55%
EPS Next Y-1.05%
EPS Next 2Y-1.88%
EPS Next 3Y-3.16%
EPS Next 5Y-4.54%
Revenue 1Y (TTM)-0.22%
Revenue growth 3Y1.45%
Revenue growth 5Y2.54%
Sales Q2Q%1.3%
Revenue Next Year-7.97%
Revenue Next 2Y-5.07%
Revenue Next 3Y-5.93%
Revenue Next 5Y-5.61%
EBIT growth 1Y44.7%
EBIT growth 3Y14.87%
EBIT growth 5Y23.65%
EBIT Next Year13.96%
EBIT Next 3Y0.03%
EBIT Next 5Y-1.73%
FCF growth 1Y10.86%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y10.78%
OCF growth 3YN/A
OCF growth 5YN/A
BRISTOL-MYERS SQUIBB CO / BRM.DE FAQ
What is the fundamental rating for BRM stock?
ChartMill assigns a fundamental rating of 5 / 10 to BRM.DE.
What is the valuation status of BRISTOL-MYERS SQUIBB CO (BRM.DE) stock?
ChartMill assigns a valuation rating of 7 / 10 to BRISTOL-MYERS SQUIBB CO (BRM.DE). This can be considered as Undervalued.
How profitable is BRISTOL-MYERS SQUIBB CO (BRM.DE) stock?
BRISTOL-MYERS SQUIBB CO (BRM.DE) has a profitability rating of 6 / 10.
What is the expected EPS growth for BRISTOL-MYERS SQUIBB CO (BRM.DE) stock?
The Earnings per Share (EPS) of BRISTOL-MYERS SQUIBB CO (BRM.DE) is expected to decline by -1.05% in the next year.
Is the dividend of BRISTOL-MYERS SQUIBB CO sustainable?
The dividend rating of BRISTOL-MYERS SQUIBB CO (BRM.DE) is 7 / 10 and the dividend payout ratio is 82.81%.